Compugen Ltd. (NASDAQ:CGEN) Stock Has Consensus Price Target of $5.00

Key Points

• Analyst consensus is bullish: Five firms covering Compugen rate it an average “Buy,” with three buys, one strong buy and one hold. The average 12-month price target is $5.00, compared with the stock’s recent price of $1.96.
• Institutional ownership has increased: Several hedge funds and investment firms added to their positions, while institutional investors collectively own 12.22% of Compugen’s shares.
• Quarterly results exceeded expectations: Compugen reported a quarterly loss of $0.07 per share versus the $0.08 expected loss and generated $2.60 million in revenue, above the $1.28 million consensus estimate.

Compugen Ltd. (NASDAQ:CGEN - Get Free Report) has been assigned an average rating of "Buy" from the five research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $5.00.

CGEN has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $4.00 target price on shares of Compugen in a research note on Monday, October 12th. Weiss Ratings raised shares of Compugen from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th.

Institutional Trading of Compugen

A number of large investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its stake in shares of Compugen by 12.1% in the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company's stock valued at $3,478,000 after acquiring an additional 176,088 shares in the last quarter. WINTON GROUP Ltd boosted its holdings in Compugen by 26.0% in the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company's stock valued at $422,000 after purchasing an additional 40,614 shares during the period. Platform Technology Partners boosted its holdings in Compugen by 10.0% in the first quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 5,000 shares during the period. Squarepoint Ops LLC acquired a new position in Compugen during the 2nd quarter worth $110,000. Finally, Glenmede Trust Co. NA grew its stake in Compugen by 187.5% during the 1st quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company's stock worth $73,000 after purchasing an additional 22,500 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company's stock.

Compugen Price Performance

NASDAQ CGEN opened at $1.96 on Friday. The company has a market cap of $185.32 million, a P/E ratio of 5.16 and a beta of 2.78. The stock has a 50-day moving average of $2.41 and a two-hundred day moving average of $2.43. Compugen has a 1-year low of $1.43 and a 1-year high of $3.23.

Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $2.60 million during the quarter, compared to analyst estimates of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%. During the same quarter last year, the firm posted ($0.08) earnings per share. On average, analysts anticipate that Compugen will post -0.28 EPS for the current fiscal year.

About Compugen

Compugen Ltd. NASDAQ: CGEN is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases involving the immune system. The company uses computational biology and artificial intelligence-driven approaches to identify potential drug targets and develop antibody-based immunotherapies designed to restore or enhance the immune system's ability to recognize and attack tumors.

Compugen's pipeline has included investigational immune checkpoint and immuno-oncology programs, including COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.